A decade of progress in tissue engineering
Crossref DOI link: https://doi.org/10.1038/nprot.2016.123
Published Online: 2016-09-01
Published Print: 2016-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Khademhosseini, Ali
Langer, Robert
Text and Data Mining valid from 2016-09-01
Version of Record valid from 2016-09-01
Article History
Received: 3 May 2016
Accepted: 8 June 2016
First Online: 1 September 2016
Competing interests
: R.L. has equity ownership in In Vivo Therapeutics, Humacyte and Sigilon.